After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Published Date: 25 Dec 2023

Additionally, in frontline settings, bispecific antibodies exhibit high response rates.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

2.

Regular physical activity before cancer diagnosis may lower progression and death risks

3.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

4.

A new theranostic drug targets different cancer types.

5.

Pickleball program boosts health and wellness for cancer survivors, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot